The design of APPLAUDS, the ﬁrst phase 2 study evaluating an RNA interference (RNAi) therapeutic in people with Down syndrome (DS) and early-stage Alzheimer disease (AD), was presented at the 2026 Alzheimer&#39;s Association International Conference (AAIC) in London.